NCT03898297Completed
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This research study is designed to look at the involvement of the glutamate system and synaptic density in depression and bipolar disorder. Each participant will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of a combination of one magnetic resonance imaging (MRI) or functional magnetic resonance imaging (fMRI) scan, one proton magnetic resonance spectroscopy (MRS) and/or one C13 MRS scans, and up to two positron emission tomography (PET) scans. Participants will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 79 (actual)
- First submitted
- 21 Dec 2018
- Start date
- 11 Jan 2017
- Primary completion date
- 8 Oct 2024
- Lead sponsor
- Yale University
- Diseases
- Depression, Bipolar disorder
- NCT number
- NCT03898297
What you commit to
- Study type: Observational
- Participants enrolled: 79
- From 11 Jan 2017 to the primary completion date, 8 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year
- Current, past, or anticipated exposure to radiation in the work place within one year of proposed research PET scans
- History of a bleeding disorder or currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
Other illness
- Current or past significant medical, neurological, or metabolic disorder
- history of head injury that led to significant long term decline in cognitive abilities as seen by decline in grades or work performance
- history of significant medical illness such that would contraindicate study participation based on above criteria and PI/MD history review
- Met Diagnostic and Statistical Manual of Mental Disorders(DSM)-5 criteria for mild substance use disorder in the past 6 months or moderate to severe substance use disorder within the past year (except marijuana or nicotine)
Other
- Active, significant suicidal ideation
- Implanted metallic devices or any MR contraindications
- women who are pregnant or breastfeeding
- Blood donation within 8 weeks of the start of the study
Who the study is looking for
- General inclusion criteria:
- 18-80 years old English speaking
- -Inclusion criteria for healthy controls: no current, or history of any DSM-5 diagnosis
- Inclusion criteria for MDD subjects clinical diagnosis of major depressive disorder
- Inclusion criteria for bipolar subjects clinical diagnosis of bipolar disorder
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale University PET Center Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.